| (-)-Syringaresinol |
|
|
|
99.93% |
| (E/Z)-BIO-acetoxime |
|
|
|
99% |
| (E/Z)-GSK-3β inhibitor 1 |
|
|
|
99.10% |
| (R)-(+)-O-Demethylbuchenavianine |
|
|
|
98.67% |
| (R)-BRD3731 |
|
|
|
98.22% |
| (Rac)-BRD0705 |
|
|
|
|
| 1-Azakenpaullone |
|
|
|
99.61% |
| 10-Hydroxy-2-decenoic acid |
|
|
|
99.93% |
| 18BIOder |
|
|
|
|
| 2-Cyanoethylalsterpaullone |
|
|
|
|
| 2B-(SP) |
|
|
|
|
| 2B-(SP) TFA |
|
|
|
|
| Bisindolylmaleimide I hydrochloride |
|
|
|
98.44% |
| 3-Methylthienyl-carbonyl-JNJ-7706621 |
|
|
|
|
| 3F8 |
|
|
|
|
| 5-Iodo-indirubin-3'-monoxime |
|
|
|
98.12% |
| 6-Me-ATP |
|
|
|
|
| 6-Me-ATP trisodium solution (100 mM) |
|
|
|
99.89% |
| 6-Methoxy-4-methylcoumarin |
|
|
|
99.00% |
| 7BIO |
|
|
|
99.20% |
| Sexangularetin 3-sophoroside |
|
|
|
|
| 8012–3246 |
|
|
|
99.72% |
| 9-Hydroxycanthin-6-one |
|
|
|
|
| 9-ING-41 |
|
|
|
99.13% |
| A 1070722 |
|
|
|
99.87% |
| A 1070722 (Standard) |
|
|
|
|
| ABC1183 |
|
|
|
99.62% |
| AChE/BACE1/GSK3β-IN-1 |
|
|
|
|
| AChE/BChE-IN-37 |
|
|
|
|
| AChE/GSK-3β-IN-1 |
|
|
|
|
| ADGRL1-IN-1 |
|
|
|
|
| AKI-062a |
|
|
|
|
| Aloisine A |
|
|
|
|
| Aloisine RP106 |
|
|
|
|
| Alsterpaullone |
|
|
|
99.85% |
| Amsacrine isethionate |
|
|
|
|
| Amsacrine lactate |
|
|
|
|
| Antitrypanosomal agent 14 |
|
|
|
|
| Antitrypanosomal agent 31 |
|
|
|
|
| AR-A014418 |
|
|
|
99.21% |
| AR-A014418-d3 |
|
|
|
|
| ARN25068 |
|
|
|
98.19% |
| ARN25657 |
|
|
|
|
| ARN25699 |
|
|
|
|
| AZ12943203 |
|
|
|
|
| AZD1080 |
|
|
|
99.16% |
| AZD1080-d8 |
|
|
|
|
| AZD2858 |
|
|
|
99.44% |
| BChE-IN-49 |
|
|
|
|
| Benarthin |
|
|
|
95.79% |
| Bikinin |
|
|
|
99.95% |
| BIO-acetoxime |
|
|
|
98.0% |
| BIP-135 |
|
|
|
99.38% |
| Bisindolylmaleimide I |
|
|
|
98.15% |
| Bisphenol F |
|
|
|
99.93% |
| Bisphenol F (Standard) |
|
|
|
98% |
| Bisphenol F-13C12 |
|
|
|
|
| Bisphenol F-13C6 |
|
|
|
|
| BMP agonist 1 |
|
|
|
|
| BMPR2-IN-1 |
|
|
|
|
| BMPR2-IN-1 TFA |
|
|
|
99.40% |
| BRD0209 |
|
|
|
99.63% |
| BRD0705 |
|
|
|
99.86% |
| BRD1172 |
|
|
|
|
| BRD1652 |
|
|
|
|
| BRD3731 |
|
|
|
98.18% |
| BRD5648 |
|
|
|
99.94% |
| Butrin |
|
|
|
|
| C-Peptide 1 (rat) |
|
|
|
99.96% |
| C24:1-Ceramide |
|
|
|
99.91% |
| CAY10594 |
|
|
|
98.64% |
| Cazpaullone |
|
|
|
|
| CDK5-IN-4 |
|
|
|
|
| CDK7-IN-20 |
|
|
|
|
| CDK8-IN-12 |
|
|
|
99.74% |
| ChE/GSK-3β-IN-1 |
|
|
|
|
| CHIR 98024 |
|
|
|
99.20% |
| CHIR-21208 |
|
|
|
|
| CHIR-98014 |
|
|
|
98.44% |
| CHIR-98023 |
|
|
|
|
| Chrysomycin A |
|
|
|
98.0% |
| COB-187 |
|
|
|
95.0% |
| CP21R7 |
|
|
|
99.74% |
| CT-1 |
|
|
|
99.90% |
| Cu(II)GTSM |
|
|
|
95% |
| Dammarenediol II |
|
|
|
99.81% |
| Degalactotigonin |
|
|
|
|
| DIF-3 |
|
|
|
99.84% |
| DTB-acid |
|
|
|
|
| EHT 5372 |
|
|
|
97.38% |
| Erlotinib-d4 |
|
|
|
|
| ES-072 |
|
|
|
98.05% |
| Ethyl linoleate |
|
|
|
99.72% |
| FRATtide |
|
|
|
|
| Fyn-IN-1 |
|
|
|
|
| Ganglioside GQ1b (bovine) sodium |
|
|
|
98% |
| Gigantol |
|
|
|
99.79% |
| Ginsenoside F2 |
|
|
|
99.92% |
| Ginsenoside Rg4 |
|
|
|
99.94% |
| GNF4877 |
|
|
|
99.82% |
| GNF7156 |
|
|
|
|
| Gomisin N |
|
|
|
99.94% |
| GS87 |
|
|
|
99.81% |
| GSK 3 Inhibitor IX |
|
|
|
99.47% |
| GSK-3 inhibitor 1 |
|
|
|
99.16% |
| GSK-3 inhibitor 3 |
|
|
|
99.10% |
| GSK-3 inhibitor 4 |
|
|
|
99.02% |
| GSK-3 inhibitor 6 |
|
|
|
|
| GSK-3 inhibitor 7 |
|
|
|
|
| GSK-3 Inhibitor XIII |
|
|
|
98.79% |
| GSK-3/CDK5/CDK2-IN-1 |
|
|
|
98.10% |
| GSK-3b Inhibitor XI |
|
|
|
95.60% |
| GSK-3α/β-IN-1 |
|
|
|
|
| GSK-3β inhibitor 1 |
|
|
|
98.82% |
| GSK-3β inhibitor 10 |
|
|
|
98.04% |
| GSK-3β inhibitor 11 |
|
|
|
98.02% |
| GSK-3β inhibitor 12 |
|
|
|
99.81% |
| GSK-3β inhibitor 13 |
|
|
|
99.74% |
| GSK-3β inhibitor 14 |
|
|
|
≥97.0% |
| GSK-3β inhibitor 15 |
|
|
|
|
| GSK-3β inhibitor 16 |
|
|
|
|
| GSK-3β inhibitor 17 |
|
|
|
|
| GSK-3β inhibitor 18 |
|
|
|
|
| GSK-3β inhibitor 19 |
|
|
|
|
| GSK-3β inhibitor 2 |
|
|
|
97.68% |
| GSK-3β inhibitor 20 |
|
|
|
|
| GSK-3β inhibitor 21 |
|
|
|
|
| GSK-3β inhibitor 22 |
|
|
|
99.38% |
| GSK-3β inhibitor 23 |
|
|
|
99.88% |
| GSK-3β inhibitor 24 |
|
|
|
|
| GSK-3β inhibitor 25 |
|
|
|
|
| GSK-3β inhibitor 26 |
|
|
|
|
| GSK-3β inhibitor 27 |
|
|
|
|
| GSK-3β inhibitor 3 |
|
|
|
99.22% |
| GSK-3β inhibitor 6 |
|
|
|
|
| GSK-3β inhibitor 7 |
|
|
|
|
| GSK-3β inhibitor 8 |
|
|
|
98.16% |
| GSK-3β probe-1 |
|
|
|
|
| GSK-3β-IN-28 |
|
|
|
|
| GSK-3β-IN-29 |
|
|
|
|
| GSK-3β/CK-1δ-IN-1 |
|
|
|
|
| GSK-3β/G9a-IN-1 |
|
|
|
|
| GSK-3β/HDAC-IN-1 |
|
|
|
|
| GSK-3β/HDAC-IN-2 |
|
|
|
|
| GSK2646264 |
|
|
|
99.74% |
| GSK3 ligand-1 |
|
|
|
|
| GSK3 Substrate, α, β subunit |
|
|
|
99.87% |
| GSK3-IN-1 |
|
|
|
99.05% |
| GSK3-IN-10 |
|
|
|
|
| GSK3-IN-11 |
|
|
|
|
| GSK3-IN-2 |
|
|
|
99.87% |
| GSK3-IN-3 |
|
|
|
99.22% |
| GSK3-IN-4 |
|
|
|
|
| GSK3-IN-7 |
|
|
|
99.35% |
| GSK3-IN-9 |
|
|
|
99.36% |
| GSK3A Human Pre-designed siRNA Set A |
|
|
|
|
| Gsk3a Mouse Pre-designed siRNA Set A |
|
|
|
|
| Gsk3a Rat Pre-designed siRNA Set A |
|
|
|
|
| GSK3β inhibitor II |
|
|
|
99.49% |
| GSK3β-IN-1 |
|
|
|
|
| GSK3β-IN-2 |
|
|
|
98.75% |
| GSK3β-IN-3 |
|
|
|
|
| GSK3β-IN-4 |
|
|
|
|
| GSK3β-peptide |
|
|
|
99.69% |
| GSK3β/mTOR modulator 1 |
|
|
|
|
| GTGKT |
|
|
|
|
| hAChE-IN-5 |
|
|
|
|
| hAChE-IN-6 |
|
|
|
|
| hAChE/hBuChE/GSK-3β-IN-1 |
|
|
|
|
| Hispidin |
|
|
|
99.85% |
| hSMG-1 inhibitor 11j |
|
|
|
99.82% |
| HTH-01-091 |
|
|
|
99.81% |
| HTH-01-091 TFA |
|
|
|
98.01% |
| IM-12 |
|
|
|
|
| IM-12 |
|
|
|
99.30% |
| Indazole |
|
|
|
99.83% |
| Indirubin-3'-monoxime |
|
|
|
99.80% |
| Indirubin-3'-monoxime-5-sulphonic acid |
|
|
|
|
| Indirubin-3′-oxime |
|
|
|
99.10% |
| Indirubin-5-sulfonate |
|
|
|
|
| Isoandrographolide |
|
|
|
98.34% |
| Isoeucommin A |
|
|
|
|
| JGK-263 |
|
|
|
|
| JNK3 inhibitor-5 |
|
|
|
|
| JNK3 inhibitor-9 |
|
|
|
|
| JNK3/Wnt/β-catenin modulator-1 |
|
|
|
|
| JZ19 |
|
|
|
|
| K00546 |
|
|
|
99.48% |
| KS-133 |
|
|
|
98.75% |
| KY19382 |
|
|
|
98.0% |
| L803-mts |
|
|
|
99.98% |
| Laduviglusib |
|
|
|
99.46% |
| Laduviglusib |
|
|
|
|
| Laduviglusib dihydrochloride |
|
|
|
|
| Laduviglusib monohydrochloride |
|
|
|
99.93% |
| Laduviglusib trihydrochloride |
|
|
|
99.11% |
| Laduviglusib-d4 |
|
|
|
|
| Leucettine L41 |
|
|
|
98.98% |
| Levistolide A |
|
|
|
99.34% |
| Lignarenone B |
|
|
|
|
| LQB-118 |
|
|
|
|
| LY2090314 |
|
|
|
|
| LY2090314 |
|
|
|
99.85% |
| Manzamine A |
|
|
|
98.2% |
| Manzamine A hydrochloride |
|
|
|
99.66% |
| MAO-B-IN-43 |
|
|
|
|
| MeBIO |
|
|
|
98.0% |
| MJ04 |
|
|
|
98.08% |
| MJ34 |
|
|
|
|
| MK-2206 |
|
|
|
99.72% |
| MK-2206 dihydrochloride |
|
|
|
99.94% |
| MK-2206 free base |
|
|
|
|
| MLS-2064 |
|
|
|
|
| Mocravimod |
|
|
|
98.39% |
| Mocravimod hydrochloride |
|
|
|
99.99% |
| MRT68921 |
|
|
|
98.09% |
| MRT68921 dihydrochloride |
|
|
|
99.67% |
| MRT68921 hydrochloride |
|
|
|
|
| Multi-kinase-IN-13 |
|
|
|
|
| Multi-kinase-IN-14 |
|
|
|
|
| Multi-kinase-IN-7 |
|
|
|
|
| Multitarget AD-IN-7 |
|
|
|
|
| Nef-M1 |
|
|
|
|
| Nodosin |
|
|
|
98.61% |
| Nordentatin |
|
|
|
|
| NSC693868 |
|
|
|
99.0% |
| PAV-174 |
|
|
|
|
| PF-04802367 |
|
|
|
98.43% |
| PfGSK3/PfPK6-IN-1 |
|
|
|
99.38% |
| PfGSK3/PfPK6-IN-2 |
|
|
|
|
| PHA-793887 hydrochloride |
|
|
|
|
| Phospho-Glycogen Synthase Peptide-2 (substrate) |
|
|
|
|
| Phospho-Glycogen Synthase Peptide-2(substrate) TFA |
|
|
|
99.75% |
| PIMPC |
|
|
|
|
| PJ17 |
|
|
|
|
| PPA24 |
|
|
|
98.09% |
| Presenilin 1 (349-361) |
|
|
|
|
| PROTAC GSK-3β Degrader-1 |
|
|
|
99.05% |
| PROTAC GSK3 degrader-1 |
|
|
|
|
| Protein kinase inhibitor 11 |
|
|
|
98.28% |
| Protein kinase inhibitor 13 |
|
|
|
|
| PT-65 |
|
|
|
99.48% |
| Pterosin A |
|
|
|
94.07% |
| R547 |
|
|
|
99.57% |
| R547 mesylate |
|
|
|
|
| RGB-286638 |
|
|
|
99.67% |
| RGB-286638 free base |
|
|
|
98.09% |
| ROCK-IN-5 |
|
|
|
99.52% |
| SAR502250 |
|
|
|
99.29% |
| SB 216763 |
|
|
|
99.37% |
| SB 415286 |
|
|
|
99.46% |
| Schisantherin B |
|
|
|
99.75% |
| SCR1693 |
|
|
|
|
| Secalonic acid D |
|
|
|
99.63% |
| SF-9-2 |
|
|
|
|
| SGC-CDKL5/GSK3 |
|
|
|
98.72% |
| SGK1-IN-8 |
|
|
|
|
| SkQR1 hydroxide |
|
|
|
|
| SLK/STK10-IN-1 |
|
|
|
99.78% |
| Strictinin |
|
|
|
97.15% |
| Tagtociclib hydrate |
|
|
|
99.73% |
| TC-G 24 |
|
|
|
|
| TCS 183 |
|
|
|
|
| TCS 21311 |
|
|
|
99.49% |
| TCS2002 |
|
|
|
99.80% |
| TD114-2 |
|
|
|
|
| TDZD-8 |
|
|
|
99.76% |
| TFGF-18 |
|
|
|
|
| Tideglusib |
|
|
|
99.70% |
| Tovophyllin A |
|
|
|
|
| Triptonodiol |
|
|
|
98.0% |
| TWS119 |
|
|
|
99.89% |
| UNC10112785 |
|
|
|
|
| VP3.15 |
|
|
|
|
| VP3.15 dihydrobromide |
|
|
|
98.0% |
| Wnt/β-catenin-IN-6 |
|
|
|
98.34% |
| WS3 |
|
|
|
98.70% |
| XL-418 |
|
|
|
95.19% |
| yGsy2p-IN-H23 |
|
|
|
99.91% |
| ZDWX-25 |
|
|
|
|
| ZLWH-23 |
|
|
|
|
| α-Amyrin |
|
|
|
99.99% |
| α-Amyrin (Standard) |
|
|
|
|
| 5-Bromo-3-indoxylacetate |
|
|
|
|
| Dihydronarwedine |
|
|
|
|
| Erlotinib (Standard) |
|
|
|
99.97% |
| Erlotinib-13C6 |
|
|
|
|
| Erlotinib-d6 |
|
|
|
99.83% |
| Erlotinib-d8 |
|
|
|
|
| Erlotinib |
|
|
|
99.96% |
| Erlotinib mesylate |
|
|
|
|
| Soyasaponin Ba |
|
|
|
99.47% |
| Ceftriaxone-13C2,d3 triethylammonium salt |
|
|
|
|
| Ceftriaxone |
|
|
|
99.87% |
| Ceftriaxone sodium hydrate |
|
|
|
99.47% |
| Ceftriaxone sodium salt |
|
|
|
99.90% |
| Kaempferide |
|
|
|
99.80% |
| Acenocoumarol-d4 |
|
|
|
|
| Acenocoumarol-d5 |
|
|
|
|
| Acenocoumarol |
|
|
|
99.17% |
| Neoandrographolide |
|
|
|
99.41% |
| Kuwanon G |
|
|
|
99.45% |
| Lithium chloride hydrate |
|
|
|
99.56% |
| Erlotinib Hydrochloride |
|
|
|
99.94% |
| Erlotinib Hydrochloride (Standard) |
|
|
|
99.73% |
| Erlotinib-d6 hydrochloride |
|
|
|
98.13% |
| Erlotinib-13C6 hydrochloride |
|
|
|
|
| Penehyclidine hydrochloride |
|
|
|
99.2% |
| Sodium thiosulfate (99%, water≤1.0%) |
|
|
|
99.89% |
| Sodium thiosulfate (98%) |
|
|
|
98.30% |
| Kenpaullone |
|
|
|
98.20% |
| Dehydroandrographolide succinate |
|
|
|
99.34% |
| Cromolyn |
|
|
|
99.97% |
| Cromolyn-d5 |
|
|
|
|
| Cromolyn disodium |
|
|
|
99.98% |
| (E)-Methyl 4-coumarate |
|
|
|
99.87% |
| (E)-Methyl 4-coumarate (Standard) |
|
|
|
99.94% |
| Bakkenolide A |
|
|
|
99.99% |
| Resibufogenin |
|
|
|
99.93% |
| Physalin B |
|
|
|
97.20% |
| Eupalinolide B |
|
|
|
99.27% |